BACKGROUND: The number of circulating endothelial progenitor cells (EPCs) has been identified as a surrogate biologic marker for vascular function and cumulative cardiovascular (CV) risk in the general population. Patients with end-stage renal disease (ESRD) on hemodialysis (HD) have markedly decreased EPC counts and function. We hypothesized that the number of circulating EPCs predicts death from all causes and CV events in patients with ESRD on HD. METHODS: We quantified the EPCs in blood samples from 70 patients with ESRD on HD. Circulating EPCs were counted by flow cytometry as the number of CD45(low)CD34(+)VEGFR2(+) cells. Death from all causes and CV events served as outcome variables over a median follow-up period of 20 months. RESULTS: It has been postulated that the number of circulating EPCs at baseline ranged from 1 to 350 cells/200 μl, with a mean of ± standard deviation (SD) of 26.0 ± 48.2 cells/200 μl. The median, lowest and highest tertiles of EPC counts were 11.0, 9.0, and 17.0 cells/200 μl, respectively. Patients with the lowest tertile EPC counts had significantly higher rates of CV events, but mortality was similar between the two groups. After adjusting for these risk factors, HbA1c and the lowest tertile EPC count remained as independent predictors of CV events. A cutoff value of 9.5 cells/200 μl maximized the power of the EPC count to predict future CV events as determined by ROC curve analysis. CONCLUSIONS: Reduced circulating EPC counts independently predicted CV events in 70 patients with ESRD on maintenance HD. Circulating EPCs may play a role in vascular repair, thereby affecting the clinical course of CV events. 2015 S. Karger AG, Basel.
BACKGROUND: The number of circulating endothelial progenitor cells (EPCs) has been identified as a surrogate biologic marker for vascular function and cumulative cardiovascular (CV) risk in the general population. Patients with end-stage renal disease (ESRD) on hemodialysis (HD) have markedly decreased EPC counts and function. We hypothesized that the number of circulating EPCs predicts death from all causes and CV events in patients with ESRD on HD. METHODS: We quantified the EPCs in blood samples from 70 patients with ESRD on HD. Circulating EPCs were counted by flow cytometry as the number of CD45(low)CD34(+)VEGFR2(+) cells. Death from all causes and CV events served as outcome variables over a median follow-up period of 20 months. RESULTS: It has been postulated that the number of circulating EPCs at baseline ranged from 1 to 350 cells/200 μl, with a mean of ± standard deviation (SD) of 26.0 ± 48.2 cells/200 μl. The median, lowest and highest tertiles of EPC counts were 11.0, 9.0, and 17.0 cells/200 μl, respectively. Patients with the lowest tertile EPC counts had significantly higher rates of CV events, but mortality was similar between the two groups. After adjusting for these risk factors, HbA1c and the lowest tertile EPC count remained as independent predictors of CV events. A cutoff value of 9.5 cells/200 μl maximized the power of the EPC count to predict future CV events as determined by ROC curve analysis. CONCLUSIONS: Reduced circulating EPC counts independently predicted CV events in 70 patients with ESRD on maintenance HD. Circulating EPCs may play a role in vascular repair, thereby affecting the clinical course of CV events. 2015 S. Karger AG, Basel.
Authors: Amrilmaen Badawi; Osfred C Jefferson; Brooke M Huuskes; Sharon D Ricardo; Peter G Kerr; Chrishan S Samuel; Padma Murthi Journal: Biomedicines Date: 2022-04-12
Authors: Albert Topf; Moritz Mirna; Bernhard Ohnewein; Peter Jirak; Kristen Kopp; Dzeneta Fejzic; Michael Haslinger; Lukas J Motloch; Uta C Hoppe; Alexander Berezin; Michael Lichtenauer Journal: Front Cardiovasc Med Date: 2020-12-04
Authors: Zhenhua Huang; Zhihao Liu; Keke Wang; Zi Ye; Yan Xiong; Bin Zhang; Jinli Liao; Lijing Zeng; Haitao Zeng; Gexiu Liu; Hong Zhan; Zhen Yang Journal: Front Cardiovasc Med Date: 2021-03-29
Authors: Brooke M Huuskes; Ryan J DeBuque; Kevan R Polkinghorne; Chrishan S Samuel; Peter G Kerr; Sharon D Ricardo Journal: Kidney Int Rep Date: 2017-09-18